| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisals TA665: Upadacitinib for treating severe rheumatoid arthritis and TA744: Upadacitinib for previously treated moderate active rheumatoid arthritis |
|
Medicine details |
|
| Medicine name | upadaticinib (Rinvoq) |
| Formulation | prolonged release tablet |
| Reference number | 3172 |
| Indication | Treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs. Rinvoq may be used as monotherapy or in combination with methotrexate |
| Company | Abbvie Ltd |
| BNF chapter | Musculoskeletal & joint diseases |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 16/04/2020 |
| NICE guidance | TA665: Upadacitinib for treating severe rheumatoid arthritis TA744: Upadacitinib for previously treated moderate active rheumatoid arthritis |
| Commercial arrangement | PAS |